Phoenix Asia Holdings Limited Announces Entering into Stock Acquisition Agreement and Convertible Promissory Note
Rhea-AI Summary
Phoenix Asia Holdings (NASDAQ: PHOE) on May 4, 2026 announced it signed a Stock Acquisition Agreement to buy 100% of ACEA Pharma, a clinical-stage pharmaceutical company, and entered a $20,000,000 convertible promissory note with its controlling stockholder, Phoenix Prosperity Investment Limited.
The acquisition adds oncology, autoimmune and COVID-19 assets; the Note provides immediate funding from the controlling shareholder.
Positive
- Agreement to acquire 100% of ACEA Pharma expands pipeline into oncology, autoimmune and COVID-19
- Secured $20,000,000 convertible note from controlling stockholder provides near-term funding
Negative
- Acquiring a clinical-stage company introduces clinical and regulatory development risk
- Convertible note may lead to future share dilution if converted, depending on terms
News Market Reaction – PHOE
In the May 5 session, PHOE gained 168.51%, reflecting a significant positive market reaction. Argus tracked a peak move of +262.2% during that session. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 17.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Earnings update | Negative | +4.7% | Reported revenue, gross profit, and net income declines for six-month period. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history: a prior earnings update with weaker fundamentals still saw a positive price reaction, indicating at least one instance where the stock rose on negative operational data.
Recent disclosures centered on financial pressure and governance build-out. A 6-K on 2026-03-31 detailed weaker unaudited results for the six months ended September 30, 2025, with declining revenue, gross profit, and net income alongside higher expenses. Despite this, the 2026-03-31 earnings news (news_id 1033928) saw shares rise 4.71%. Multiple Form 3 filings in March–April 2026 formalized insider reporting status, reflecting evolving board and management structure ahead of today’s acquisition and financing announcement.
Key Terms
stock acquisition agreement financial
convertible promissory note financial
autoimmune disease medical
covid-19 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hong Kong, May 04, 2026 (GLOBE NEWSWIRE) -- Phoenix Asia Holdings Limited (the “Company” or “Phoenix Asia”) (NASDAQ: PHOE), a Hong Kong-based company mainly engaged in substructure works, announces a significant update in its business development.
Phoenix Asia is pleased to announce entering into a stock acquisition agreement (the “Stock Acquisition Agreement”) with ACEA Pharma, Inc., an exempted company incorporated with limited liability in the Cayman Islands (“Target Company”) and ACEA Therapeutics, Inc., an exempted company incorporated with limited liability in the Cayman Islands (the “Transferor”) for the acquisition of
The Company is also pleased to announce entering into a convertible promissory note with a principal sum of
About the Stock Acquisition Agreement
On May 4, 2026, the Company entered into the Stock Acquisition Agreement with (i) the Target Company; and (ii) the Transferor. The Transferor holds
The closing of the Stock Acquisition Agreement is expected to take place in the second quarter of 2026, subject to the satisfaction of the customary closing conditions and the receipt of all necessary regulatory approvals, including without limitation, that (i) all applicable waiting periods (and any extensions thereof) under the Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and all other applicable antitrust or merger control laws shall have expired or otherwise been terminated and (ii) the receipt of any approval, clearance, confirmation, or other determination from Nasdaq to the extent required in connection with the transactions contemplated by the Stock Acquisition Agreement (including with respect to any reverse merger, reverse takeover, change of control or similar review).
About the Convertible Promissory Note
On May 4, 2026, the Company issued the Note in favor of the Holder with a principal sum of
About Phoenix Asia Holdings Limited
Phoenix Asia Holdings Limited is a Hong Kong-based company mainly engaged in substructure works, such as site formation, ground investigation and foundation works, in Hong Kong. The Company strives to deliver unparalleled customer satisfaction, the highest standards of work and safety, and exceptional craftsmanship and environmental performance. The Company conducts its business through its wholly-owned Hong Kong operating subsidiaries, Winfield Engineering (Hong Kong) Limited. Subsequent to this acquisition, the Company intends to transform into a pharmaceutical-industry holding company.
For more information, please visit the Company’s website: https://ir.winfield.hk.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements regarding the satisfaction of closing conditions, the receipt of regulatory approvals (including approvals by Nasdaq), the timing and completion of the transaction and the conversion of the Note. These statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, including risks discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission.
For more information, please contact:
Phoenix Asia Holdings Limited
Investor Relations Department
Email: ir@winfield.hk
